Investigational drug · Phase 2
RSS0393
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Psoriatic Subjects, Plaque Psoriasis in Children, Plaque Psoriasis in Adolescents.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
5
Any phase or sponsor naming "RSS0393"
First trial start
2025
Apr 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RSS0393", any sponsor or status.
Conditions studied
As listed on its trial records.
- Psoriatic Subjects
- Plaque Psoriasis in Children
- Plaque Psoriasis in Adolescents
- Atopic Dermatitis of Adults
Approved drugs for the same conditions: Plaque psoriasis · Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "RSS0393" as an intervention, largest first.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis.Pivotal-lookingNot yet recruiting
Reistone Biopharma Company LimitedIndustry
NCT07543224 · 600 participants (planned) · Start Apr 2026 · Primary completion Jan 2027
Drug: RSS0393 ointment 0.03%; RSS0393 ointment placebo · For: Plaque Psoriasis Subjects
Sites: Beijing, China
- A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic DermatitisPivotal-lookingCompleted
Reistone Biopharma Company LimitedIndustry
NCT07158151 · 168 participants · Start Sep 25, 2025 · Primary completion Apr 10, 2026
Drug: RSS0393 ointment; RSS0393 ointment and 2 more · For: Atopic Dermatitis of Adults
Sites: Guangzhou, China
- To Evaluate the Efficacy and Safety of RSS0393 Ointment in Patients With Plaque Psoriasis Phase II StudyPivotal-lookingNot yet recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06918743 · 147 participants (planned) · Start Apr 2025 · Primary completion Mar 2026
Drug: RSS0393 ointment; RSS0393 ointment and 1 more · For: Psoriatic Subjects
- Randomized, Double-blind, Placebo-controlled Study of RSS0393 Ointment in Healthy and Psoriatic SubjectsActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06308393 · 98 participants · Start Mar 1, 2024 · Primary completion Dec 2025
Drug: RSS0393 ointment;Placebo · For: Healthy; Psoriatic Subjects
Sites: Hefei, China; Shanghai, China
- A Clinical Study to Evaluate the Safety and Pharmacokinetics of Topical RSS0393 Ointment in Children and Adolescents With Plaque PsoriasisNot yet recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07102888 · 20 participants (planned) · Start Aug 2025 · Primary completion Feb 2026
Drug: RSS0393 Ointment · For: Plaque Psoriasis in Children; Plaque Psoriasis in Adolescents
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.